High Blood Pressure

Winter can raise blood pressure by several points, increasing heart attack and stroke risk. Doctors outline the causes and practical ways to stay protected

Cardiologists warn that high-caffeine drinks may trigger heart strain and blood-pressure spikes, especially in young people

Researchers say widespread or long-term pain may be a major yet overlooked risk factor for hypertension, calling for better pain care and routine blood pressure checks

A major meta-analysis shows hypertension has surged from just over 3% to more than 6% among people under 19, raising urgent concerns for parents, schools, and health systems

Prevalence of hypertension or high blood pressure among children and teenagers has nearly doubled in the last two decades, from 3.2 per cent in 2000 to over six per cent in 2020, according to a global analysis published in The Lancet Child and Adolescent Health journal. Left unaddressed, hypertension can lead to cardiovascular and kidney disease. Estimates also suggest that nearly a fifth of the world's children and adolescents with obesity have hypertension -- about eight times the prevalence among those having a healthy weight (2.4 per cent), researchers including those from the UK's University of Edinburgh said. The findings suggest obesity is a substantial driver of the increase in childhood hypertension. Obesity tends to cause other issues, such as insulin resistance and changes in blood vessels, which can make it harder to maintain a healthy blood pressure. Further, eight per cent of children and teenagers around the world may be having pre-hypertension, which is a warning si

Over a third of India's children aged 5-9 could be having high triglycerides, with Jammu and Kashmir, West Bengal and northeastern states showing highest prevalence, according to a government report. Over 67 per cent of children in West Bengal, 64 per cent in Sikkim, 55 per cent in Nagaland, 57 per cent in Assam and 50 per cent in Jammu Kashmir were estimated to have high levels of triglycerides -- a type of blood fat that is known to increase risk of heart disease in later life. Kerala and Maharashtra were among the states showing lowest prevalence at 16.6 per cent and 19.1 per cent, respectively. 'Children in India 2025' -- the fourth edition since its start in 2008 -- was released by the Ministry of Statistics and Programme Implementation during the 29th Conference of Central and State Statistical Organisations (CoCSSO) on September 25 in Chandigarh. The report "provides a comprehensive and detailed analysis of the well-being of children in the country," the ministry said in a .

Baxdrostat lowered systolic blood pressure by 9-10 mmHg in trials and could benefit Indian patients with resistant hypertension by reducing side effects of older drugs

Doctors highlight that a thicker neck may reflect hidden fat distribution in the body, raising chances of insulin resistance, high blood pressure, and cardiovascular disease

High blood pressure can be managed without pills. From the DASH diet to yoga and weight loss, here are proven lifestyle changes to lower BP

The American Heart Association now advises personalised care, home monitoring, and lifestyle-first strategies to curb the growing burden of hypertension

Zydus Lifesciences on Monday said it has received approval from the US health regulator to market a drug used to treat angina and high blood pressure. The company has received final approval from the US Food and Drug Administration (USFDA) for Diltiazem Hydrochloride tablets in strengths of 30 mg, 60 mg, 90 mg, and 120 mg, the drug maker said in a statement. Diltiazem Hydrochloride Tablets are indicated for the management of chronic stable angina and angina due to coronary artery spasm. It belongs to a class of drugs called calcium-channel blockers. Diltiazem works by relaxing blood vessels, which reduces the workload on the heart and increases blood and oxygen supply to the heart muscle. The company said Diltiazem Hydrochloride Tablets will be produced at Zydus Lifesciences' Baddi plant in Himachal Pradesh. As per IQVIA MAT June 2025 data, Diltiazem Hydrochloride Tablets had annual sales of USD 13.9 million in the US.

Hypertension affects over 220 million Indians but few get diagnosed or treated in time-here's how to understand and manage both high and low BP

World Hypertension Day is marked annually on May 17 to raise awareness about high BP, its risks, and the significance of early detection and effective management

High blood pressure impairs one's breathing capacity by hardening the airways in the respiratory system, thereby increasing resistance, a study has found. However, being physically active can help by improving the functioning of respiratory muscles, resulting in better coordination between ventilation and blood flow in the lungs, researchers from the Federal University of Sao Paulo, Brazil, found. Hypertension, in which one's blood pressure remains unusually high, is known to thicken the blood vessels and harden the arteries. The researchers said that something similar happens with the bronchi -- branches of the main windpipe (trachea) -- in the respiratory system as well. "This is very important as the more hardened the bronchi becomes, the more difficult it becomes for air to enter and leave the lungs. In the long run, this accelerated process of hardening of the bronchi makes breathing difficult for older people. Worse still, it's a cycle: lower oxygen saturation accelerates the

World Hypertension Day 2024: This day is celebrated every year to raise awareness about the risk of hypertension and its preventive measures. Here's all you need to know about this day

Glenmark Pharmaceuticals is recalling 6,528 bottles of a medication used to treat high blood pressure in the American market due to failed dissolution specifications, the US health regulator said. The US-based arm of the Mumbai-headquartered drug firm is recalling the affected lot of Diltiazem Hydrochloride extended-release capsules, the US Food and Drug Administration said in its latest Enforcement Report. The affected lot has been produced in India and is being recalled by New Jersey-based Glenmark Pharmaceuticals Inc for "failed dissolution specifications", the USFDA said. "Out of Specification (OOS) was reported in a test of dissolution at the 12th month time point in long-term stability study," it noted. Glenmark initiated Class II recall of the drug across the US on March 26 this year. As per the USFDA, a Class II recall is initiated in a situation in which the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences

This is the first study to compare the development and risk factors associated with persistent high blood pressure in people with Covid-19 infection to influenza, a similar respiratory virus

Pharma major Lupin Ltd on Wednesday said it has received approval from the US health regulator to market its generic Metoprolol Succinate extended-release tablets used for lowering blood pressure. The approval by the US Food and Drug Administration (USFDA) for the abbreviated new drug application is for Metoprolol Succinate extended-release tablets of strengths 25 mg, 50 mg, 100 mg, and 200 mg, Lupin said in a regulatory filing. These are generic equivalent of Toprol-XL Tablets of Sequel Therapeutics, LLC. This product will be manufactured at Lupin's Pithampur facility in India, the company said. Metoprolol Succinate extended-release tablets had an estimated annual sales of USD 305 million in the US, the company said citing IQVIA MAT June 2023 data.

World hypertension day is observed on May 17 every year. Read more about its history, theme and exercises to combat high blood pressure

Drug firm Granules India on Monday said it has received approval from the US health regulator to market a generic product to treat high blood pressure. The company has received approval from the US Food & Drug Administration (USFDA) to market Losartan Potassium tablets in strengths of 25 mg, 50 mg, and 100 mg, Granules India said in a regulatory filing. The Hyderabad-based company's product is bioequivalent to the Organon LLC's Cozaar tablets. According to IQVIA/IMS Health, the current annual US market for Losartan potassium tablets is around USD 336 million. Shares of the company were trading 1.24 per cent down at Rs 281.75 apiece on the BSE.